16 results
10-K
2021 FY
DRMA
Dermata Therapeutics Inc
28 Mar 22
Annual report
8:33am
recall that could occur;
costs of operating as a public company;
the emergence, approval, availability, perceived advantages, relative cost, relative … or detain products or require us or our partners to initiate a product recall.
The regulations, policies or guidance of the FDA and other applicable
DRS
DRMA
Dermata Therapeutics Inc
2 Apr 21
Draft registration statement
12:00am
recall that could occur;
costs of operating as a public company;
the emergence, approval, availability, perceived advantages, relative cost … to initiate a product recall.
The regulations, policies or guidance of the FDA and other applicable government agencies may change and new or additional
DRS/A
DRMA
Dermata Therapeutics Inc
7 May 21
Draft registration statement (amended)
12:00am
become involved in and any damages payable by us that result from such litigation;
costs associated with any product recall that could occur;
costs … or detain products or require us or our partners to initiate a product recall.
The regulations, policies or guidance of the FDA and other applicable
424B4
5pbx8t8d52 ca3sp
13 May 22
Prospectus supplement with pricing info
5:06pm
424B4
229k9um7p565hmbg1z
16 Aug 21
Prospectus supplement with pricing info
4:54pm
S-1
83902m 1ybhz1ubc0i
10 Jun 21
IPO registration
5:11pm
DRS
so57 9yzpa821s1u
11 Jan 22
Draft registration statement
12:00am
8-K
EX-10.1
51ww2tfac
25 Apr 22
Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
4:45pm
8-K
EX-10.1
mb03a iejitpxezd
24 May 23
Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
5:13pm
- Prev
- 1
- Next